Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Seaside Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01706523
First received: October 10, 2012
Last updated: July 30, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2013
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)